tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

PVLA Stock Latest News

Palvella Therapeutics initiated with a Buy at Chardan
The FlyPalvella Therapeutics initiated with a Buy at Chardan
1d ago
PVLA
Palvella Therapeutics price target raised to $53 from $39 at Canaccord
PremiumThe Fly
Palvella Therapeutics price target raised to $53 from $39 at Canaccord
8d ago
PVLA
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
PremiumRatings
Palvella Therapeutics: Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating
9d ago
PVLA
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
PremiumRatings
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
9d ago
PVLA
Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
PremiumThe Fly
Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
10d ago
PVLA
Palvella Therapeutics Reports 2024 Financial Results and Updates
PremiumCompany AnnouncementsPalvella Therapeutics Reports 2024 Financial Results and Updates
10d ago
8K
PVLA
Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)
Premium
The Fly
Palvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)
10d ago
PVLA
Palvella Therapeutics initiated with a Buy at Stifel
Premium
The Fly
Palvella Therapeutics initiated with a Buy at Stifel
16d ago
PVLA
Palvella Therapeutics initiated with a Buy at JonesResearch
PremiumThe Fly
Palvella Therapeutics initiated with a Buy at JonesResearch
16d ago
PVLA
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
PremiumThe Fly
Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
1M ago
W
AL
Positive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential
PremiumRatings
Positive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential
1M ago
PVLA
Palvella Therapeutics initiated with an Outperform at Scotiabank
PremiumThe Fly
Palvella Therapeutics initiated with an Outperform at Scotiabank
1M ago
KRYS
PVLA
Palvella Therapeutics Enhances Investor Relations with New Presentation
PremiumCompany AnnouncementsPalvella Therapeutics Enhances Investor Relations with New Presentation
1M ago
8K
PVLA
Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise
Premium
Ratings
Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise
1M ago
PVLA
Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
Premium
The Fly
Palantir initiated, Roku upgraded: Wall Street’s top analyst calls
2M ago
CE
BAX
Canaccord starts Palvella Therapeutics with a Buy on lead programs’ potential
PremiumThe Fly
Canaccord starts Palvella Therapeutics with a Buy on lead programs’ potential
2M ago
PVLA
Palvella Therapeutics initiated with a Buy at Canaccord
PremiumThe Fly
Palvella Therapeutics initiated with a Buy at Canaccord
2M ago
PVLA
Palvella Therapeutics to expand Phase 3 SELVA trial to include younger patients
PremiumThe Fly
Palvella Therapeutics to expand Phase 3 SELVA trial to include younger patients
2M ago
PVLA
Palvella Therapeutics initiated with a Buy at TD Cowen
PremiumThe Fly
Palvella Therapeutics initiated with a Buy at TD Cowen
2M ago
PVLA
Promising Potential of Palvella Therapeutics’ QTORIN Platform Drives Buy Rating
PremiumRatingsPromising Potential of Palvella Therapeutics’ QTORIN Platform Drives Buy Rating
2M ago
PVLA
Four new option listings and one option delisting on January 29th
Premium
The Fly
Four new option listings and one option delisting on January 29th
2M ago
GOEV
JAVA
Palvella Therapeutics announces results from Phase 2 study of QTORIN
Premium
The Fly
Palvella Therapeutics announces results from Phase 2 study of QTORIN
3M ago
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >